A pilot study of gestational diabetes mellitus not controlled by diet alone: First-line medical treatment with myoinositol may limit the need for insulin

Diabetes and Metabolism

Volumn 42, Issue 3, 2016, Pages 192-195

  Lubin, V ^a   Shojai, R ^a   Darmon, P ^b   Cosson, E ^c  

^a Clinique de l étoile   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Diabetes; Gestational diabetes mellitus; Insulin; Macrosomia; Myoinositol; Pregnancy

Indexed keywords

FOLIC ACID; GLUCOSE; INOSITOL; INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; FEMALE; HUMAN; INSULIN TREATMENT; LABOR INDUCTION; MATERNAL NUTRITION; PILOT STUDY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PROSPECTIVE STUDY; BLOOD; DIABETES, GESTATIONAL; DIET; DIET THERAPY; FRANCE; MULTIMODALITY CANCER THERAPY; PREGNANCY;

ADULT; BLOOD GLUCOSE SELF-MONITORING; COMBINED MODALITY THERAPY; DIABETES, GESTATIONAL; DIET; FEMALE; FOLIC ACID; FRANCE; HUMANS; INOSITOL; INSULIN; PILOT PROJECTS; PREGNANCY; PREGNANCY OUTCOME;

EID: 84959386317     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.01.005     Document Type: Article

References (14)

1. Ben-Haroush A., Yogev Y., Hod M. Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med 2004, 21:103-113.
2. Croze M.L., Soulage C.O. Potential role and therapeutic interests of myoinositol in metabolic diseases. Biochimie 2013, 95:1811-1827.
3. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myoinositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012, 28:509-515.
4. Zheng X., Liu Z., Zhang Y., Lin Y., Song J., Zheng L., et al. Relationship between myoinositol supplementary and gestational diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2015, 94:e1604.
5. Cosson E. Diagnostic criteria for gestational diabetes mellitus. Diabetes Metab 2010, 36:538-548.
6. Gestational diabetes. Summary of expert consensus. Diabetes Metab 2010, 36:695-699.
7. Corrado F., D'Anna R., Di Vieste G., Giordano D., Pintaudi B., Santamaria A., et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 2011, 28:972-975.
8. D'Anna R., Di Benedetto V., Rizzo P., Raffone E., Interdonato M.L., Corrado F., et al. Myoinositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012, 28:440-442.
9. Matarrelli B., Vitacolonna E., D'Angelo M., Pavone G., Mattei P.A., Liberati M., et al. Effect of dietary myoinositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 2013, 26:967-972.
10. D'Anna R., Scilipoti A., Giordano D., Caruso C., Cannata M.L., Interdonato M.L., et al. Myoinositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 2013, 36:854-857.
11. D'Anna R., Di Benedetto A., Scilipoti A., Santamaria A., Interdonato M.L., Petrella E., et al. Myoinositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Obstet Gynecol 2015, 126:310-315.
12. Scioscia M., Kunjara S., Gumaa K., McLean P., Rodeck C.H., Rademacher T.W. Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitus. Diabet Med 2007, 24:1300-1304.
13. Cosson E., Cussac-Pillegand C., Benbara A., Pharisien I., Nguyen M.T., Chiheb S., et al. Pregnancy adverse outcomes related to pregravid body mass index and gestational weight gain, according to the presence or not of gestational diabetes mellitus: a retrospective observational study. Diabetes Metab 2016, 42(1):38-46. [Epub 2015 Jul 2]. 10.1016/j.diabet.2015.06.001.
14. Chavey A., Ah Kioon M.D., Bailbe D., Movassat J., Portha B. Maternal diabetes, programming of beta-cell disorders and intergenerational risk of type 2 diabetes. Diabetes Metab 2014, 40:323-330.